MacroGenics announced positive interim results from its Phase 2 LINNET study of lorigerlimab in advanced clear cell gynecologic cancer (CCGC), showing a 25% confirmed objective response rate and 44% disease control rate. The drug demonstrated a manageable safety profile with some treatment-related adverse events, and all responses were ongoing at the data cutoff. MacroGenics is continuing the study with a lower dose and expects to share updated results in the first half of 2027. These findings highlight lorigerlimab's potential as a new treatment option for this aggressive and hard-to-treat cancer subtype.
MacroGenics' lorigerlimab in advanced clear cell gynecologic cancer is reported with positive interim Phase 2 results. For readers following the health sector, here is Pluang's market snapshot as of Oct 26, 2026 18:11 WIB: out of 150 priced US health stocks, 82 rose and 35 fell today. Notable prices include ADPT at USD 25.07 with a 1-day change of -1.72% and a typical hold time of 37 days, IMVT at USD 28.03 with a -1.34% change and 17 days hold time, and JNJ at USD 266.99 with a +1.21% change and 130 days hold time.
Senseonics Holdings has begun the first human clinical trial of Freedom, a next-generation continuous glucose monitoring (CGM) system designed without an external on-body transmitter. This implantable device communicates directly with mobile devices ...
Stryker Corporation has finalized its acquisition of ZuriMED, incorporating the FiberLocker System into its Sports Medicine offerings. This technology enhances rotator cuff repair by improving biomechanical strength, addressing a key clinical need. T...
Kratos Defense & Security Solutions announced it will release its third quarter 2026 financial results after market close on November 5, 2026. The company will hold a conference call at 2:00 p.m. Pacific Time to discuss its operations and financial p...
FOREWARN, a safety solutions provider for real estate professionals, introduced Community Alerts, a new feature that allows agents to flag phone numbers after concerning interactions. This alert is instantly shared across its network of over 443,000 ...
Franklin Electric Co., Inc. announced a quarterly cash dividend of $0.28 per share, payable on November 19, 2026, to shareholders of record as of November 5, 2026. This dividend reflects the company's ongoing commitment to returning value to its shar...
